Speakers
Dr Rani Khatib Consultant Pharmacist in Cardiology & Cardiovascular Research, Leeds Teaching Hospitals NHS Trust
Dr Dermot Neely Specialist Adviser on lipids to Academic Health Science Network – North-East and North Cumbria
Learning objectives
-
- Understand the national lipid management pathway, and primary and secondary prevention of cardiovascular disease
- Understand when non-statin therapeutic approaches may be indicated in clinical practice
- Identify the patient groups who may benefit from non-statin lipid-lowering therapeutic options
Learning module instructions
This BJC TV Learning module has a recommended award of 1 CPD credit for completion (1 hour of learning). Completion requires a score of at least 80%. If less time is spent learning, then you should claim a reduced credit value. After you have successfully completed the test you will be able to download your certificate.
Quiz Summary
0 of 4 Questions completed
Questions:
Information
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
Results
Results
0 of 4 Questions answered correctly
Your time:
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
Categories
- Not categorized 0%
- 1
- 2
- 3
- 4
- Current
- Review
- Answered
- Correct
- Incorrect
-
Question 1 of 4
1. Question
1. For every 1 mmol/L reduction of low-density lipoprotein cholesterol (LDL-C), what is the corresponding relative risk reduction in atherosclerotic cardiovascular disease after 1 year?
CorrectIncorrect -
Question 2 of 4
2. Question
2. When may non-statin lipid-lowering therapies be indicated?
CorrectIncorrect -
Question 3 of 4
3. Question
3. Which routine investigations should be offered in patients receiving lipid-lowering therapy, and how frequently should they be offered, according to the national guidance for lipid management in CVD?
CorrectIncorrect -
Question 4 of 4
4. Question
4. What are the latest cost-effective targets of lipid-lowering therapy for secondary prevention of cardiovascular disease, according to updated NICE guidelines?
CorrectIncorrect
References
- NHS England. Improving lipid management to reduce cardiovascular disease and save lives. 2023. Available at: https://www.england.nhs.uk/long-read/improving-lipid-management-to-reduce-cardiovascular-disease-and-save-lives/ (accessed February 2024)
- NICE. CKS. Lipid modification – CVD prevention: Statins. 2023. Available at: https://cks.nice.org.uk/topics/lipid-modification-cvd-prevention/prescribing-information/statins/ (accessed February 2024)
- NHS England. Summary of National Guidance for Lipid Management for Primary and Secondary Prevention of CVD. Available at: https://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2020/04/lipid-management-pathway-v6.pdf (accessed February 2024)
- NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification [NG238]. December 2023. Available at: https://www.nice.org.uk/guidance/ng238/chapter/Recommendations (accessed February 2024)